These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 32706898)

  • 21. Functional and Morphologic Findings at Four Years After Intravitreal Bevacizumab or Laser for Type 1 ROP.
    Lepore D; Ji MH; Quinn GE; Amorelli GM; Orazi L; Ricci D; Mercuri E
    Ophthalmic Surg Lasers Imaging Retina; 2020 Mar; 51(3):180-186. PubMed ID: 32211908
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of Intravitreal Bevacizumab, Intravitreal Ranibizumab and Laser Photocoagulation for Treatment of Type 1 Retinopathy of Prematurity in Turkish Preterm Children.
    Kabataş EU; Kurtul BE; Altıaylık Özer P; Kabataş N
    Curr Eye Res; 2017 Jul; 42(7):1054-1058. PubMed ID: 28128986
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Update on the Use of Anti-VEGF Drugs in the Treatment of Retinopathy of Prematurity.
    Seery CW; Betesh S; Guo S; Zarbin MA; Bhagat N; Wagner RS
    J Pediatr Ophthalmol Strabismus; 2020 Nov; 57(6):351-362. PubMed ID: 33211892
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reactivation of retinopathy of prematurity after ranibizumab treatment.
    Wong RK; Hubschman S; Tsui I
    Retina; 2015 Apr; 35(4):675-80. PubMed ID: 25768252
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Histopathological analysis of retinopathy of prematurity after intravitreal bevacizumab.
    Bee CR; Burris CKH; Potter HAD; Reddy D; Simons KB; Costakos DM
    J AAPOS; 2017 Apr; 21(2):159-160. PubMed ID: 28219740
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
    Sankar MJ; Sankar J; Mehta M; Bhat V; Srinivasan R
    Cochrane Database Syst Rev; 2016; 2():CD009734. PubMed ID: 26932750
    [TBL] [Abstract][Full Text] [Related]  

  • 27. RATES AND RISK FACTORS FOR RECURRENCE OF RETINOPATHY OF PREMATURITY AFTER LASER OR INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR MONOTHERAPY.
    Ling KP; Liao PJ; Wang NK; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC; Wu WC
    Retina; 2020 Sep; 40(9):1793-1803. PubMed ID: 31800460
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ranibizumab in retinopathy of prematurity - one-year follow-up of ophthalmic outcomes and two-year follow-up of neurodevelopmental outcomes from the CARE-ROP study.
    Stahl A; Bründer MC; Lagrèze WA; Molnár FE; Barth T; Eter N; Guthoff R; Krohne TU; Pfeil JM;
    Acta Ophthalmol; 2022 Feb; 100(1):e91-e99. PubMed ID: 33742551
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low dose versus conventional dose of intravitreal bevacizumab injection for retinopathy of prematurity: a case series with paired-eye comparison.
    Han J; Kim SE; Lee SC; Lee CS
    Acta Ophthalmol; 2018 Jun; 96(4):e475-e478. PubMed ID: 27011262
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Practice Patterns and Outcomes of Intravitreal Anti-VEGF Injection for Retinopathy of Prematurity: An International Multicenter Study.
    Patel NA; Acaba-Berrocal LA; Hoyek S; Fan KC; Martinez-Castellanos MA; Baumal CR; Harper CA; Berrocal AM;
    Ophthalmology; 2022 Dec; 129(12):1380-1388. PubMed ID: 35863512
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intravitreal bevacizumab injection in aggressive posterior retinopathy of prematurity compared with type I retinopathy of prematurity.
    Eftekhari Milani A; Hassanpoor N; Mousavi Mirkala M; Taheri A; Golizade A; Niyousha MR
    Int Ophthalmol; 2020 Feb; 40(2):477-482. PubMed ID: 31712928
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preliminary anatomical and neurodevelopmental outcomes of intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity.
    Araz-Ersan B; Kir N; Tuncer S; Aydinoglu-Candan O; Yildiz-Inec D; Akdogan B; Ekici B; Demirel A; Ozmen M
    Curr Eye Res; 2015 May; 40(6):585-91. PubMed ID: 25025864
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Effects of intravitreal pegaptanib or bevacizumab and laser in treatment of threshold retinopathy of prematurity in zone I and posterior zone II--four years results].
    Autrata R; Senková K; Holousová M; Krejcírová I; Dolezel Z; Borek I
    Cesk Slov Oftalmol; 2012 Feb; 68(1):29-36. PubMed ID: 22679695
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intravitreal bevacizumab monotherapy for retinopathy of prematurity.
    Şahin A; Şahin M; Cingü AK; Çınar Y; Türkcü FM; Yüksel H; Kaya S; Arı Ş; Caça İ
    Pediatr Int; 2013 Oct; 55(5):599-603. PubMed ID: 23659781
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sequential Short Interval Anti-VEGF for the Treatment of Stage 4 Retinopathy of Prematurity.
    Hamichi SE; Saigal K; Anzaldo EF; Gold A; Berrocal AM; Murray TG
    Ophthalmic Surg Lasers Imaging Retina; 2022 Mar; 53(3):159-163. PubMed ID: 35272561
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Study protocol for prognosis and treatment strategy of peripheral persistent avascular retina after intravitreal anti-VEGF therapy in retinopathy of prematurity.
    Yu Y; Wang J; Chen F; Chen W; Jiang N; Xiang D
    Trials; 2020 Jun; 21(1):493. PubMed ID: 32513245
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Two-Year Outcomes Comparing Anti-VEGF Injections to Laser for ROP Using a Commercial Claims Database.
    Zhang MH; Blair MP; Ham SA; Rodriguez SH
    Ophthalmic Surg Lasers Imaging Retina; 2020 Sep; 51(9):486-493. PubMed ID: 32955587
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined intravitreal bevacizumab injection and zone I sparing laser photocoagulation in patients with zone I retinopathy of prematurity.
    Kim J; Kim SJ; Chang YS; Park WS
    Retina; 2014 Jan; 34(1):77-82. PubMed ID: 23807184
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of Recurrent Retinopathy of Prematurity Following Anti-VEGF Injection.
    Bhatt AR; Paul Chan RV; Reynolds JD; Wagner RS
    J Pediatr Ophthalmol Strabismus; 2019 Mar; 56(2):68-70. PubMed ID: 30889257
    [No Abstract]   [Full Text] [Related]  

  • 40. Comparison of efficacy between anti-vascular endothelial growth factor (VEGF) and laser treatment in Type-1 and threshold retinopathy of prematurity (ROP).
    Li Z; Zhang Y; Liao Y; Zeng R; Zeng P; Lan Y
    BMC Ophthalmol; 2018 Jan; 18(1):19. PubMed ID: 29378530
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.